Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

SRPT

NASDAQ

Sarepta Therapeutics (SRPT)

13.34 USD −5.83% vs prior close Nov 20, 2026
Sarepta Therapeutics, Inc. price graph
64 sessions
25 10 24 Aug 20 Nov

The line runs 18.12 USD on 24 August through 13.34 USD on 20 November, on a scale from 10 to 25. Days the market did not trade hold the previous close, flat.

Market cap
1.4B USD
Revenue, year to Dec 2025
1.9B USD
EPS, diluted, year to Dec 2025
−7.13 USD
52-week range
13.34 USD – 24 USD
Avg volume
122.1K
Mentions, 30 days
1

as of Nov 20, 2026

Have Sarepta Therapeutics (SRPT) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, no Sarepta Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest Form 4 filing 4 Sep 2026

0buys
0sells
4other filings
Have Sarepta Therapeutics (SRPT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
04 Sep 2026Wong Ryan Ho-YanChief Financial OfficerTax withheld13,272295K USD
04 Sep 2026Estepan Ian MichaelChief Operating OfficerTax withheld24,799551K USD
04 Sep 2026Rothfuss CristinEVP, General CounselTax withheld22,025489K USD
04 Sep 2026Rodino-Klapac LouisePresident, R&D and Tech OpsTax withheld21,423476K USD

Which funds hold Sarepta Therapeutics (SRPT)?

8 of the 45 institutional funds we track reported a Sarepta Therapeutics position for the quarter ended 30 Sep 2026 — a combined 209.7M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Sarepta Therapeutics (SRPT)?
FundPositionSharesValueShares q/q
Two Sigma InvestmentsHeld (±25%)4,475,96581.6M USD−2.7%
Balyasny Asset ManagementAdded2,452,56044.7M USD+1,510.6%
Marshall WaceHeld (±25%)2,015,95036.7M USD−8.6%
Point72 Asset ManagementAdded805,75914.7M USD+57.7%
Bridgewater AssociatesAdded595,64810.9M USD+291.7%
Renaissance TechnologiesTrimmed454,2788.3M USD−59.5%
AQR Capital ManagementTrimmed395,6747.2M USD−90.9%
Millennium ManagementTrimmed311,1065.7M USD−73.9%
Man GroupExited

Have members of Congress traded Sarepta Therapeutics (SRPT)?

The most recent congressional trade disclosed in Sarepta Therapeutics is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 14 Apr 2025.

STOCK Act disclosures

Have members of Congress traded Sarepta Therapeutics (SRPT)?
TradedMemberTypeAmountFiled after
14 Apr 2025Gilbert Ray Cisneros, Jr.house · Democrat–CASale1K USD–15K USD22 days
14 Jul 2023Josh Gottheimerhouse · Democrat–NJPurchase1K USD–15K USD38 days
13 Jun 2023Josh Gottheimerhouse · Democrat–NJSale1K USD–15K USD28 days
06 Mar 2023Josh Gottheimerhouse · Democrat–NJPurchase1K USD–15K USD45 days
06 Mar 2023Daniel S. Goldmanhouse · Democrat–NYPurchase15K USD–50K USD42 days
31 Jan 2023Daniel S. Goldmanhouse · Democrat–NYSale1K USD–15K USD24 days
14 Sep 2020Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD30 days
10 Oct 2019Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD36 days

What has been filed or recorded for Sarepta Therapeutics (SRPT)?

The filings we hold for Sarepta Therapeutics, newest first: 3 fails-to-deliver days, 4 quarterly earnings reports, 3 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Sarepta Therapeutics (SRPT)?
And
30 Oct 2026Fails to deliverShares failed to deliver2,783 shares54K USD notional · 0.003% of shares out
28 Oct 2026Fails to deliverShares failed to deliver11,085 shares209K USD notional · 0.010% of shares out
15 Oct 2026Fails to deliverShares failed to deliver6,934 shares117K USD notional · 0.006% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.27 USDRevenue $381M
30 Sep 2026FinancialsTotal assets3.2B USDat period end
30 Sep 2026FinancialsTotal equity1.5B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.05 USDRevenue $401M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 2.88 USDRevenue $731M
31 Dec 2025Annual reportFY 2025 reportedEPS −3.93 USDRevenue $443M
31 Dec 2025FinancialsRevenue1.9B USDfiscal year
31 Dec 2025FinancialsNet income−713.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−7.13 USDfiscal year
30 Sep 2025Annual reportFY 2025 reportedEPS −0.50 USDRevenue $399M
30 Jun 2025Annual reportFY 2025 reportedEPS 1.89 USDRevenue $611M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −4.60 USDRevenue $745M

What is Reddit saying about Sarepta Therapeutics (SRPT)?

Reddit mentioned SRPT 1 times in the 30 days to 21 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 0% read bullish, 100% bearish and 0% neither. Reddit data updated 21 November 2026.

30-day window, Method

1mentions, 30 days
1communities

How do Reddit mentions of Sarepta Therapeutics (SRPT) compare with its price?

Share ↗
1 mentions

Which subreddits are talking about Sarepta Therapeutics (SRPT)?

30 days

Which subreddits are talking about Sarepta Therapeutics (SRPT)?
CommunityShareMentionsNet sentiment
r/wallstreetbets100%1−0.36

What do people ask about Sarepta Therapeutics (SRPT)?

From live data
What did Sarepta Therapeutics shares close at?13.34

Sarepta Therapeutics closed at 13.34 USD on 20 Nov 2026, down 5.83% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Sarepta Therapeutics’ market cap?1.4B

Sarepta Therapeutics is worth 1.4B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Sarepta Therapeutics’ revenue?1.9B

Sarepta Therapeutics reported revenue of 1.9B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Sarepta Therapeutics insiders bought or sold shares recently?4 filings

In the 90 days to 22 Nov 2026, no Sarepta Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders

Which funds own Sarepta Therapeutics?8 of 45

8 of the 45 funds we track reported a Sarepta Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Balyasny Asset Management and Marshall Wace. See Funds

Have members of Congress traded Sarepta Therapeutics?10 trades

Yes. 10 trades in Sarepta Therapeutics appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 14 Apr 2025, filed 6 May 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Sarepta Therapeutics last report earnings?−0.27

Sarepta Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.27 USD; no next date is announced in SEC filings yet. See Filings

What is Reddit saying about Sarepta Therapeutics?0 mentions

Sarepta Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 0% read bullish and 100% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. RedditReddit ingest across the tracked finance subreddits
  4. SEC EDGARForm 4 filings (insider transactions)
  5. SEC EDGAR13F filings
  6. Wikimedia CommonsPortraits via Wikimedia Commons. Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain; Daniel S. Goldman: US House, Public domain; Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain.
  7. House disclosuresU.S. House of Representatives financial disclosures
  8. SECSEC fails-to-deliver (CNS) data
  9. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  10. SEC EDGARreported earnings figures and scheduled report dates
  11. SEC EDGARValuation computed from SEC EDGAR filings
  12. Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Sarepta_Therapeutics